UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-05, Vol.22 (3), p.527-535

2019

Link zum Volltext

Verfügbarkeit prüfen

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

BMC cancer, 2019-04, Vol.19 (1), p.292-292, Article 292

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

Oncoimmunology, 2024-12, Vol.13 (1), p.2371563

2024

Link zum Volltext

Verfügbarkeit prüfen

Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018-05, Vol.21 (3), p.453-463

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study

Liver cancer (Basel ), 2021-04, Vol.10 (2), p.107-114

2021

Link zum Volltext

Verfügbarkeit prüfen

Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021, Vol.24 (1), p.156-167

2021

Link zum Volltext

Verfügbarkeit prüfen

Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study

Cancers, 2020-07, Vol.12 (7), p.1968

2020

Link zum Volltext

Verfügbarkeit prüfen

Detection and evaluation of signals for immune-related adverse events: a nationwide, population-based study

Frontiers in oncology, 2023, Vol.13, p.1295923-1295923

2023

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY

Cancers, 2022-01, Vol.14 (3), p.559

2022

Link zum Volltext

Verfügbarkeit prüfen

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma

Hepatology communications, 2020-07, Vol.4 (7), p.1073-1086

2020

Link zum Volltext

Verfügbarkeit prüfen

613 A phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A698-A698

2023

Link zum Volltext

Verfügbarkeit prüfen

Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis

Therapeutic advances in medical oncology, 2022, Vol.14, p.17588359221097934-17588359221097934

2022

Link zum Volltext

Verfügbarkeit prüfen

Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

Targeted oncology, 2021-05, Vol.16 (3), p.401-410

2021

Link zum Volltext

Verfügbarkeit prüfen

Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma

Cancer medicine (Malden, MA), 2021-03, Vol.10 (5), p.1745-1758

2021

Link zum Volltext

Verfügbarkeit prüfen

HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells

BMB reports, 2018-12, Vol.51 (12), p.660-665

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Survival and Tumor Recurrence in Patients with Superficial Esophageal Cancer after Complete Non-Curative Endoscopic Resection: A Single-Center Case Series

Clinical Endoscopy, 2018, 51(5), , pp.470-477

2018

Link zum Volltext

Verfügbarkeit prüfen

Preoperative plasma fibrinogen level is a useful predictor of adjacent organ involvement in patients with advanced gastric cancer

Journal of Gastric Cancer, 2012, 12(2), , pp.81-87

2012

Link zum Volltext

Verfügbarkeit prüfen

Helicobacter pylori Seropositivity Is Associated with Gastric Cancer Regardless of Tumor Subtype in Korea

Gut and Liver, 2010, 4(4), , pp.466-474

2010

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of cabozantinib in advanced hepatocellular carcinoma: Korean real-world study

International journal of surgery (London, England), 2022-04, Vol.100, p.106378, Article 106378

2022

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO)

Anticancer research, 2019-09, Vol.39 (9), p.5123-5133

2019

Link zum Volltext

Verfügbarkeit prüfen

Definitive chemoradiotherapy versus esophagectomy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma: A retrospective study

Radiotherapy and oncology, 2021-09, Vol.162, p.112-118

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT159: Open label, single-arm, multi-center phase Ib/II study to evaluate the safety and efficacy of nivolumab in combination with paclitaxel in Epstein-Barr virus (EBV)-related, or microsatellite instability-high (MSI-H), or programmed cell death ligand 1 (PD-L1) positive advanced gastric cancer (AGC)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT159-CT159

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular‐cholangiocarcinoma

Liver international, 2021-06, Vol.41 (6), p.1398-1408

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 125

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(118)
Mit Volltextzugriff
(123)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment

Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study

Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)

Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study

Detection and evaluation of signals for immune-related adverse events: a nationwide, population-based study

A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma

613 A phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)

Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis

Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma

HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells

Correction to: Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis

Long-Term Survival and Tumor Recurrence in Patients with Superficial Esophageal Cancer after Complete Non-Curative Endoscopic Resection: A Single-Center Case Series

Preoperative plasma fibrinogen level is a useful predictor of adjacent organ involvement in patients with advanced gastric cancer

Helicobacter pylori Seropositivity Is Associated with Gastric Cancer Regardless of Tumor Subtype in Korea

Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery

Efficacy and safety of cabozantinib in advanced hepatocellular carcinoma: Korean real-world study

A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO)

Definitive chemoradiotherapy versus esophagectomy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma: A retrospective study

Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular‐cholangiocarcinoma

Aktive Filter

Suchergebnisse filtern